Patents by Inventor Matthias Hochgurtel

Matthias Hochgurtel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterobicyclic metalloprotease inhibitors
    Patent number: 8835441
    Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: September 16, 2014
    Assignee: Amgen Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • HETEROBICYCLIC METALLOPROTEASE INHIBITORS
    Publication number: 20120015920
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, JR., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • Dipeptidyl peptidase-IV inhibitors
    Patent number: 8076330
    Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: December 13, 2011
    Assignee: Amgen Inc.
    Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jürgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochgürtel, Fritz-Frieder Frickel, Arthur G. Taveras, Christoph Steeneck
  • Heterotricyclic Metalloprotease Inhibitors
    Publication number: 20100249102
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: April 6, 2010
    Publication date: September 30, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur Taveras
  • Heterobicyclic metalloprotease inhibitors
    Patent number: 7795245
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: September 14, 2010
    Assignee: Atlantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essors, Joshua Van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • Heterotricyclic metalloprotease inhibitors
    Patent number: 7749996
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: July 6, 2010
    Assignee: Alantos Pharmaceutical Holdings, Inc.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, Jr., Irving Sucholeiki, Arthur Taveras
  • Heterobicyclic metalloprotease inhibitors
    Patent number: 7713966
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: May 11, 2010
    Assignee: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Jr., Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgürtel, Bert Nolte, Arthur Taveras
  • Heterotricyclic Metalloprotease Inhibitors
    Publication number: 20100087420
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: December 4, 2009
    Publication date: April 8, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur G. Taveras
  • Heterobicyclic Metalloprotease Inhibitors
    Publication number: 20090312312
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: February 12, 2009
    Publication date: December 17, 2009
    Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.
    Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
  • Heterobicyclic metalloprotease inhibitors
    Publication number: 20080261968
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: October 23, 2008
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgurtel, Bert Nolte, Arthur Taveras
  • Metalloprotease inhibitors containing a squaramide moiety
    Publication number: 20080221094
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a squaramide moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Harald Bluhm, Christian Gege, Matthias Hochgurtel, Arthur Taveras
  • Metalloprotease inhibitors containing a heterocyclic moiety
    Publication number: 20080221093
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Harald Bluhm, Matthias Hochgurtel, Matthias Schneider, Carine Chevrier, Arthur Taveras
  • Heterobicyclic metalloprotease inhibitors
    Publication number: 20080221092
    Abstract: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: September 11, 2008
    Inventors: Harald Bluhm, Matthias Hochgurtel, Heiko Kroth, Michael Essers, Christian Gege, Frank Richter, Arthur Taveras
  • Heterobicyclic metalloprotease inhibitors
    Publication number: 20080221083
    Abstract: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: September 11, 2008
    Inventors: Matthias Hochgurtel, Harald Bluhm, Heiko Kroth, Michael Essers, Christian Gege, Arthur Taveras
  • Heterotricyclic metalloprotease inhibitors
    Publication number: 20080207607
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 28, 2008
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras
  • Heterobicyclic metalloprotease inhibitors
    Publication number: 20080161300
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: December 7, 2007
    Publication date: July 3, 2008
    Applicant: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Beisinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
  • Multicyclic bis-amide MMP inhibitors
    Publication number: 20060173183
    Abstract: The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
    Type: Application
    Filed: December 30, 2005
    Publication date: August 3, 2006
    Inventors: Timothy Powers, Christoph Steeneck, Ralf Biesinger, Harald Bluhm, Hongbo Deng, Rory Dodd, Brian Gallagher, Christian Gege, Matthias Hochgurtel, Andrew Kiely, Frank Richter, Matthias Schneider, Irving Sucholeiki, Joshua Van Veldhuizen, Xinyuan Wu, Arthur Taveras